Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.50 |
| ▸ | STAT3 | P40763 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | OGA | O60502 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29858194 | 0.93 | KDM4E (0.51) | HTTALDH1A1KDM4ETSHRLMNA | |
| SCHEMBL4712990 | 0.93 | KDM4E (0.51) | HTTALDH1A1KDM4ETSHRLMNA | |
| SCHEMBL4711626 | 0.91 | CRHBP (0.53) | HTTPOLBALDH1A1KDM4ESTAT3 | |
| SCHEMBL4709810 | 0.88 | HTT (0.54) | HTTALDH1A1KDM4ETSHRLMNA | |
| SCHEMBL4710492 | 0.84 | ALDH1A1 (0.49) | POLBALDH1A1KDM4ELMNAMAPK1 | |
| SCHEMBL5182353 | 0.82 | EBP (0.52) | — | |
| SCHEMBL4712941 | 0.81 | MEN1 (0.58) | HTTPOLBALDH1A1KDM4ETSHR | |
| SCHEMBL4709136 | 0.80 | LMNA (0.58) | HTTPOLBALDH1A1KDM4ELMNA | |
| SCHEMBL14160214 | 0.79 | ALDH1A1 (0.46) | HTTALDH1A1KDM4ETSHRLMNA | |
| SCHEMBL4709200 | 0.78 | HTT (0.62) | HTTPOLBALDH1A1KDM4ESTAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1935885-A2 | Melanin concentrating hormone receptor ligands : substituted 1-benzyl-4-aryl piperazine analogues. | NEUROGEN CORPORATION (US) | 2008-06-25 | — | — | EP | claimed |
| CN-1703401-A | Substituted 1-benzyl-4-arylpiperazine analogs as ligands for melanin concentrating hormone receptors | NEUROGEN CORP (US) | 2005-11-30 | — | — | CN | claimed |
| EP-1389189-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED 1-BENZYL-4-ARYL PIPERAZINE ANALOGUES | NEUROGEN CORPORATION (US) | 2004-02-18 | — | — | EP | claimed |
| WO-2002094799-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED 1-BENZYL-4-ARYL PIPERAZINE ANALOGUES | NEUROGEN CORPORATION (US) | 2002-11-28 | — | — | WO | claimed |
| EP-1935885-A2 | Melanin concentrating hormone receptor ligands : substituted 1-benzyl-4-aryl piperazine analogues. | NEUROGEN CORPORATION (US) | 2008-06-25 | — | — | EP | disclosed |
| US-20080044353-A1 | Combination Therapy for Weight Management | NEUROGEN CORPORATION | 2008-02-21 | — | — | US | disclosed |
| EP-1729762-A4 | COMBINATION THERAPY FOR WEIGHT MANAGEMENT | NEUROGEN CORP (US) | 2007-12-19 | — | — | EP | disclosed |
| US-20070249616-A1 | Substituted 1-Benzyl-4-Substituted Piperazine Analogues | NEUROGEN CORPORATION (US) | 2007-10-25 | — | — | US | disclosed |
| US-20070249616-A1 | Substituted 1-Benzyl-4-Substituted Piperazine Analogues | NEUROGEN CORPORATION (US) | 2007-10-25 | — | — | US | disclosed |
| US-20070249616-A1 | Substituted 1-Benzyl-4-Substituted Piperazine Analogues | NEUROGEN CORPORATION (US) | 2007-10-25 | — | — | US | disclosed |
| US-7253168-B2 | Substituted 1-benzyl-4-substituted piperazine analogues | NEUROGEN CORPORATION (US) | 2007-08-07 | — | — | US | disclosed |
| US-7253168-B2 | Substituted 1-benzyl-4-substituted piperazine analogues | NEUROGEN CORPORATION (US) | 2007-08-07 | — | — | US | disclosed |
| US-20060009456-A1 | Aryl-substituted piperazine derivatives | NEUROGEN CORPORATION | 2006-01-12 | — | — | US | disclosed |
| CN-1703401-A | Substituted 1-benzyl-4-arylpiperazine analogs as ligands for melanin concentrating hormone receptors | NEUROGEN CORP (US) | 2005-11-30 | — | — | CN | disclosed |
| WO-2005094305-A2 | COMBINATION THERAPY FOR WEIGHT MANAGEMENT | NEUROGEN CORPORATION (US) | 2005-10-13 | — | — | WO | disclosed |
| US-6953801-B2 | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues | NEUROGEN CORPORATION (US) | 2005-10-11 | — | — | US | disclosed |
| US-20050182068-A1 | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues | HUTCHISON ALAN (US) | 2005-08-18 | — | — | US | disclosed |
| US-20050065162-A1 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED 1-BENZYL-4-ARYL PIPERAZINE ANALOGUES | NEUROGEN CORPORATION | 2005-03-24 | — | — | US | disclosed |
| EP-1389189-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED 1-BENZYL-4-ARYL PIPERAZINE ANALOGUES | NEUROGEN CORPORATION (US) | 2004-02-18 | — | — | EP | disclosed |
| WO-2002094799-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED 1-BENZYL-4-ARYL PIPERAZINE ANALOGUES | NEUROGEN CORPORATION (US) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080044353-A1 | Combination Therapy for Weight Management | CNR1, CNR2, MCHR1 | HTT 1183/4885POLB 4406/4885ALDH1A1 4220/4885 |
| US-20070249616-A1 | Substituted 1-Benzyl-4-Substituted Piperazine Analogues | MCHR1, MCHR2, PRLHR | HTT 1289/4885POLB 3884/4885ALDH1A1 793/4885 |
| US-20060009456-A1 | Aryl-substituted piperazine derivatives | MCHR1, MCHR2, PRLHR | HTT 407/4885POLB 4525/4885ALDH1A1 1364/4885 |
| US-20050065162-A1 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED 1-BENZYL-4-ARYL PIPERAZINE ANALOGUES | MCHR1, MCHR2, MC1R | HTT 368/4885POLB 4648/4885ALDH1A1 1263/4885 |
| US-20050182068-A1 | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues | MCHR1, MCHR2, MC1R | HTT 368/4885POLB 4648/4885ALDH1A1 1263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.